Cargando…
Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
The morbidity and mortality of lung cancer are increasing, seriously threatening human health and life. Non-small cell lung cancer (NSCLC) has an insidious onset and is not easy to be diagnosed in its early stage. Distant metastasis often occurs and the prognosis is poor. Radiotherapy (RT) combined...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981667/ https://www.ncbi.nlm.nih.gov/pubmed/36875059 http://dx.doi.org/10.3389/fimmu.2023.1122352 |
_version_ | 1784900157415882752 |
---|---|
author | Jie, Chen Li, Rumeng Cheng, Yajie Wang, Zhihao Wu, Qiuji Xie, Conghua |
author_facet | Jie, Chen Li, Rumeng Cheng, Yajie Wang, Zhihao Wu, Qiuji Xie, Conghua |
author_sort | Jie, Chen |
collection | PubMed |
description | The morbidity and mortality of lung cancer are increasing, seriously threatening human health and life. Non-small cell lung cancer (NSCLC) has an insidious onset and is not easy to be diagnosed in its early stage. Distant metastasis often occurs and the prognosis is poor. Radiotherapy (RT) combined with immunotherapy, especially with immune checkpoint inhibitors (ICIs), has become the focus of research in NSCLC. The efficacy of immunoradiotherapy (iRT) is promising, but further optimization is necessary. DNA methylation has been involved in immune escape and radioresistance, and becomes a game changer in iRT. In this review, we focused on the regulation of DNA methylation on ICIs treatment resistance and radioresistance in NSCLC and elucidated the potential synergistic effects of DNA methyltransferases inhibitors (DNMTis) with iRT. Taken together, we outlined evidence suggesting that a combination of DNMTis, RT, and immunotherapy could be a promising treatment strategy to improve NSCLC outcomes. |
format | Online Article Text |
id | pubmed-9981667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99816672023-03-04 Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer Jie, Chen Li, Rumeng Cheng, Yajie Wang, Zhihao Wu, Qiuji Xie, Conghua Front Immunol Immunology The morbidity and mortality of lung cancer are increasing, seriously threatening human health and life. Non-small cell lung cancer (NSCLC) has an insidious onset and is not easy to be diagnosed in its early stage. Distant metastasis often occurs and the prognosis is poor. Radiotherapy (RT) combined with immunotherapy, especially with immune checkpoint inhibitors (ICIs), has become the focus of research in NSCLC. The efficacy of immunoradiotherapy (iRT) is promising, but further optimization is necessary. DNA methylation has been involved in immune escape and radioresistance, and becomes a game changer in iRT. In this review, we focused on the regulation of DNA methylation on ICIs treatment resistance and radioresistance in NSCLC and elucidated the potential synergistic effects of DNA methyltransferases inhibitors (DNMTis) with iRT. Taken together, we outlined evidence suggesting that a combination of DNMTis, RT, and immunotherapy could be a promising treatment strategy to improve NSCLC outcomes. Frontiers Media S.A. 2023-02-17 /pmc/articles/PMC9981667/ /pubmed/36875059 http://dx.doi.org/10.3389/fimmu.2023.1122352 Text en Copyright © 2023 Jie, Li, Cheng, Wang, Wu and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jie, Chen Li, Rumeng Cheng, Yajie Wang, Zhihao Wu, Qiuji Xie, Conghua Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer |
title | Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer |
title_full | Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer |
title_fullStr | Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer |
title_full_unstemmed | Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer |
title_short | Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer |
title_sort | prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and dna methyltransferase inhibitors in non-small cell lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981667/ https://www.ncbi.nlm.nih.gov/pubmed/36875059 http://dx.doi.org/10.3389/fimmu.2023.1122352 |
work_keys_str_mv | AT jiechen prospectsandfeasibilityofsynergistictherapywithradiotherapyimmunotherapyanddnamethyltransferaseinhibitorsinnonsmallcelllungcancer AT lirumeng prospectsandfeasibilityofsynergistictherapywithradiotherapyimmunotherapyanddnamethyltransferaseinhibitorsinnonsmallcelllungcancer AT chengyajie prospectsandfeasibilityofsynergistictherapywithradiotherapyimmunotherapyanddnamethyltransferaseinhibitorsinnonsmallcelllungcancer AT wangzhihao prospectsandfeasibilityofsynergistictherapywithradiotherapyimmunotherapyanddnamethyltransferaseinhibitorsinnonsmallcelllungcancer AT wuqiuji prospectsandfeasibilityofsynergistictherapywithradiotherapyimmunotherapyanddnamethyltransferaseinhibitorsinnonsmallcelllungcancer AT xieconghua prospectsandfeasibilityofsynergistictherapywithradiotherapyimmunotherapyanddnamethyltransferaseinhibitorsinnonsmallcelllungcancer |